Find clinical trials for Alzheimer's Disease in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease

Dementia

Cognitive Dysfunction

Mental Disorders

Brain Diseases

Neurodegenerative Diseases

Psychomotor Agitation

Alzheimer's Disease trials near London, England, GBR:

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...

Begins enrollment this month

Alzheimer's Disease

Alzheimer's Disease, Familial

Drug: lecanemab

Phase 3

The Washington University

London, Greater London, United Kingdom and 7 other locations

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...

Enrolling

Prodromal Alzheimer's Disease

Alzheimer's Disease

Biological: ACI-24.060 at Dose A

Biological: ACI-24.060 at Dose D

Phase 1, Phase 2

AC Immune

London, United Kingdom and 16 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling

Alzheimers Disease

Alzheimers Disease, Familial

Drug: Solanezumab

Drug: Lecanemab

Phase 2, Phase 3

The Washington University

London, Greater London, United Kingdom and 38 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Enrolling

Alzheimers Disease

Alzheimers Disease, Familial

Drug: Lecanemab

Drug: E2814

Phase 2, Phase 3

The Washington University

London, Greater London, United Kingdom and 37 other locations

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

multiple intravenous (IV) doses of IBC-Ab002 in persons with early Alzheimer's disease. The study will have both Single- and Multip...

Enrolling

Alzheimer's Disease

Biological: IBC-Ab002

Other: Placebo

Phase 1

Immunobrain Checkpoint

London, United Kingdom and 10 other locations

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling

Preclinical Alzheimer's Disease

Early Preclinical Alzheimer's Disease

Drug: Lecanemab

Drug: Placebo

Phase 3

Eisai

London, United Kingdom and 111 other locations

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...

Enrolling

Alzheimer's Disease (AD)

Drug: ABBV-552

Drug: Placebo for ABBV-552

Phase 2

AbbVie

London, United Kingdom and 63 other locations

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

(IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE...

Enrolling

Alzheimer Disease

Drug: E2814

Phase 1, Phase 2

Eisai

London, United Kingdom and 2 other locations

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting

Alzheimer's Disease

Other: Placebo

Biological: Bepranemab

Phase 2

UCB

London, United Kingdom and 101 other locations

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting

Alzheimer's Disease

Drug: Lecanemab 2.5 mg/kg

Drug: Lecanemab 10 mg/kg

Phase 2

Eisai

London, United Kingdom and 168 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Alzheimer's Disease in .css-epvm6{white-space:nowrap;}London, England

Related conditions:

Alzheimer's Disease trials near London, England, GBR:

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Find clinical trials for Alzheimer's Disease in London, England